Thomas R Moench
Overview
Explore the profile of Thomas R Moench including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moench T, Botta L, Farrer B, Lickliter J, Kang H, Park Y, et al.
EBioMedicine
. 2025 Feb;
113:105582.
PMID: 39923743
Background: Although COVID-19 is predominantly a respiratory tract infection, current antibody treatments are administered by systemic dosing. We hypothesize that inhaled delivery of a monoclonal antibody may be a more...
2.
McSweeney M, Alnajjar S, Schaefer A, Richardson Z, Wolf W, Stewart I, et al.
Adv Sci (Weinh)
. 2024 Jan;
11(12):e2306729.
PMID: 38225749
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in infants, the immunocompromised, and the elderly. RSV infects the airway epithelium via the apical membrane and almost exclusively sheds progeny...
3.
Mausser E, Nador E, Politch J, Pauly M, Marathe J, Moench T, et al.
PLoS One
. 2023 Mar;
18(3):e0282147.
PMID: 36996137
High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use...
4.
Thurman A, Moench T, Hoke M, Politch J, Cabral H, Mausser E, et al.
Am J Obstet Gynecol
. 2023 Mar;
228(6):716.e1-716.e12.
PMID: 36870409
Background: With an unplanned pregnancy rate of 50% or more in many countries, there is an urgent need for contraceptives that are more accessible and acceptable. To meet the growing...
5.
Shrestha B, Vincent K, Schaefer A, Zhu Y, Vargas G, Motamedi M, et al.
Proc Natl Acad Sci U S A
. 2021 Nov;
118(48).
PMID: 34815336
Nonhormonal products for on-demand contraception are a global health technology gap; this unmet need motivated us to pursue the use of sperm-binding monoclonal antibodies to enable effective on-demand contraception. Here,...
6.
Shrestha B, Schaefer A, Zhu Y, Saada J, Jacobs T, Chavez E, et al.
Sci Transl Med
. 2021 Aug;
13(606).
PMID: 34380769
Many women risk unintended pregnancy because of medical contraindications or dissatisfaction with contraceptive methods, including real and perceived side effects associated with the use of exogenous hormones. We pursued direct...
7.
Baldeon-Vaca G, Marathe J, Politch J, Mausser E, Pudney J, Doud J, et al.
EBioMedicine
. 2021 Jul;
69:103478.
PMID: 34256345
Background: Approximately 40% of human pregnancies are unintended, indicating a need for more acceptable effective contraception methods. New antibody production systems make it possible to manufacture reagent-grade human monoclonal antibodies...
8.
Politch J, Cu-Uvin S, Moench T, Tashima K, Marathe J, Guthrie K, et al.
PLoS Med
. 2021 Feb;
18(2):e1003495.
PMID: 33534791
Background: MB66 film is a multipurpose prevention technology (MPT) product with monoclonal antibodies (mAbs) against HIV-1 (VRC01-N) and HSV-1 and 2 (HSV8-N). The mAbs were produced by transient expression in...
9.
Shrestha B, Schaefer A, Chavez E, Kopp A, Jacobs T, Moench T, et al.
Acta Biomater
. 2020 Sep;
117:226-234.
PMID: 32937206
Multivalent antibodies such as sIgA can crosslink motile entities such as sperm and bacteria, creating agglomerates that are too large to permeate the dense mucin matrix in mucus, a process...
10.
Anderson D, Politch J, Cone R, Zeitlin L, Lai S, Santangelo P, et al.
Biol Reprod
. 2020 Jul;
103(2):275-285.
PMID: 32607584
Sexually transmitted infections are highly prevalent, and over 40% of pregnancies are unplanned. We are producing new antibody-based multipurpose prevention technology products to address these problems and fill an unmet...